Update (4:15 p.m.): Updated with Tuesday market close information.
The FDA decided Friday to reject the company's request to grant Breakthrough status to the company's experimental melanoma drug PV-10. The New York Stock Exchange placed Provectus' listing status under review on Tuesday, and the stock resumed trading just before 11 a.m.
For more on this story, read TheStreet's Adam Feuerstein's article here.
The stock closed down 62.87% to 75 cents. More than 15 million shares changed hands, which easily surpassed the average volume of 788,894. The stock had a range of 30 cents to 87 cents for the day and holds a 52-week range of 30 cents to $6.03.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.